GlassScriptPhysician profile
Shawn D Glisson
NPI 1821061268
$5,951.83
in general payments reported to CMS, 2019-2025
25 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,860 · 2020: $1,682 · 2021: $575 · 2022: $269 · 2023: $784 · 2024: $664 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $900.00 | 2020 | |
| Genzyme Corporation | $647.36 | 2019-2025 | |
| Beigene USA, INC. | $488.10 | 2021-2024 | Brukinsa |
| Janssen Biotech, INC. | $465.89 | 2019-2023 | Rybrevant |
| Merck Sharp & Dohme LLC | $439.37 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $399.59 | 2023-2024 | Ultomiris |
| Celgene Corporation | $257.81 | 2019 | |
| Pfizer INC. | $241.75 | 2019-2024 | |
| Genentech USA, INC. | $230.71 | 2023-2024 | Polivy, Columvi |
| Eisai INC. | $225.55 | 2020 | |
| Kite Pharma, INC. | $216.43 | 2019-2022 | |
| Abbvie INC. | $194.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $187.68 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $133.62 | 2020 | |
| Rigel Pharmaceuticals, INC. | $125.29 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $124.74 | 2019 | |
| Exelixis INC. | $118.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $113.73 | 2021 | |
| Jazz Pharmaceuticals INC. | $110.08 | 2019 | |
| Emd Serono, INC. | $101.69 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $97.96 | 2021 | |
| Seagen INC. | $88.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2025 | Vpriv |
| Daiichi Sankyo INC. | $11.00 | 2019 | |
| Clovis Oncology, INC. | $6.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Glisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.